[2024/11/8] Gene and Cell Therapy- weekly digest from PackGene

Nov 8, 2024

Featured

Nov 06 Stem cells can tailor their role in gene therapy based on the underlying disease, study suggests read more »
Nov 04 HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration read more »
Nov 01 Navigating the RNA Lipid Nanoparticle Landscape read more »
News
Nov 06 Hospital-Based CGT Production the Best Option for Patients read more »
Nov 06 Research team discovers a new mechanism in cancer cell immune evasion read more »
Nov 05 Notch Therapeutics Signals a New Era in CAR-T Therapies read more »
Nov 04 What will it take to get miRNA therapies to market? | Nature Biotechnology read more »
Nov 01 Direct RNA Sequencing Supports Novel Discoveries in RNA Biology read more »
Nov 01 The Golden Age of Medicine: Advancements in Novel Modalities and Therapeutic Areas read more »
Articles
Nov 05 Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer read more »
Nov 05 Expression and distribution of rAAV9 intrathecally administered in juvenile to adolescent mice read more »
Nov 03 Decoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription read more »
Nov 01 Development of compact transcriptional effectors using high-throughput measurements in diverse contexts read more »
Oct 25 Adeno-Associated Virus Gene Transfer Ameliorates Progression of Skeletal Lesions in Mucopolysaccharidosis IVA Mice read more »
Oct 24 Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model read more »
Oct 04 AAVolve: Concatenated long-read deep sequencing enables whole capsid tracking during shuffled AAV library selection read more »

PackGene’s Newsletter

Receive the latest news and insights to your inbox.

Subscribe Now
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE